Altus Pharmaceuticals, a biopharmaceutical company engaged in the development of protein therapies for chronic gastrointestinal and metabolic disorders, priced its offering of 7 million shares at $15, the mid-point of its $14-$16 range. Merrill Lynch and Morgan ...read more
Altus Pharmaceuticals, a developer of oral and injectable protein therapeutics for chronic gastrointestinal and metabolic disorders, announced Wednesday that it will offer 6.0 million shares at a range of $14 to $16. Assuming the stock prices at the midpoint,...read more
Altus Pharmaceuticals, a developer of oral and injectable protein therapeutics for chronic gastrointestinal and metabolic disorders, registered with the SEC for an initial public offering Monday morning. The Cambridge, MA-based company has two main product...read more
Altus Medical, provider of an FDA approved laser system for hair and vein removal, withdrew its IPO Friday citing unfavorable market conditions. UBS Warburg and Lehman Brothers were the underwriters for this deal....read more
Altus Pharmaceuticals prices 7mm shares at $15
Altus Pharmaceuticals, a biopharmaceutical company engaged in the development of protein therapies for chronic gastrointestinal and metabolic disorders, priced its offering of 7 million shares at $15, the mid-point of its $14-$16 range. Merrill Lynch and Morgan ...read more
Biotech Altus Pharmaceuticals files terms
Altus Pharmaceuticals, a developer of oral and injectable protein therapeutics for chronic gastrointestinal and metabolic disorders, announced Wednesday that it will offer 6.0 million shares at a range of $14 to $16. Assuming the stock prices at the midpoint,...read more
Drug maker Altus files for IPO
Altus Pharmaceuticals, a developer of oral and injectable protein therapeutics for chronic gastrointestinal and metabolic disorders, registered with the SEC for an initial public offering Monday morning. The Cambridge, MA-based company has two main product...read more
Hair removal system provider Altus Medical withdraws IPO due to market condition
Altus Medical, provider of an FDA approved laser system for hair and vein removal, withdrew its IPO Friday citing unfavorable market conditions. UBS Warburg and Lehman Brothers were the underwriters for this deal....read more